Rhythm Pharmaceuticals, Inc. (RYTM) Stock Score, Valuation & Financial Research
Rhythm Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for RYTM
Rhythm Pharmaceuticals, Inc. currently has a Wall Street Score of 20/100. The stored market price is $96.77. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Rhythm Pharmaceuticals, Inc. does
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) d
RYTM financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $96.77
- Market capitalization:
- $6.64B
- Revenue:
- $217.2M
- Net income:
- $-202.7M
- Free cash flow:
- $-116.6M
- Cash:
- $62.1M
- Total debt:
- $227.0M
- EPS:
- -3.11
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 35/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-116.6M, showing cash burn in the current stored period.
- The balance sheet shows $62.1M of cash versus $227.0M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research RYTM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.